In a rare block­buster per­for­mance for As­traZeneca, Tagris­so comes through on lung can­cer PhI­II

For a Big Phar­ma com­pa­ny that of­ten gets things wrong, Tagris­so has been As­traZeneca’s ace in the hole. Sped through the clin­ic to a first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.